You are here: Industry Insights > Market News > Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Dry powder Inhaler(DPI)

Pressurized Metered Dose Inhaler(pMDI)

Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences

pharmaceutical-technologyAugust 04, 2017

Tag: Innoviva , Seattle Genetics , PlasmaGen BioSciences

Favorites

US-based small molecule medicines provider Innoviva (formerly Advanced Medicine) has announced a private placement of convertible senior notes due 2025 to raise $175m.

Biotechnology company Seattle Genetics plans to acquire biopharmaceutical firm Bristol-Myers Squibb’s pharmaceutical manufacturing facility located in Bothell, Washington, US.

"Biotechnology company Seattle Genetics plans to acquire biopharmaceutical firm Bristol-Myers Squibb’s pharmaceutical manufacturing facility located in Bothell, Washington, US."

The acquisition will help the company to expand its antibody drug conjugate and immuno-oncology pipeline.

PlasmaGen BioSciences Private has secured $25m through a venture financing round led by Eight Roads Ventures India.

The Indian biopharmaceutical company will use the funds for the expansion of its product portfolio.

Previous:Latest Progress of PD-1 Inhibitors: Keytruda and Opdivo are close

Next:QS Pharma receives approval from European Medicines Agency

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>